Interim Clinical Guidance for Management of Patients with Confirmed 2019 Novel Coronavirus (2019-nCoV) Infection

Revisions have been made on June 20, 2020, to mirror the next:

Revisions have been made on May 29, 2020, to mirror the next:

Revisions have been made on May 25, 2020, to mirror the next:

Revisions have been made on May 20, 2020, to mirror the next:

Revisions have been made on May 12, 2020, to mirror the next:

  • New details about COVID-19-Associated Hypercoagulability
  • Updated content material and assets to incorporate new NIH Treatment Guidelines
  • Minor revisions for readability

This interim steerage is for clinicians caring for sufferers with confirmed an infection with extreme acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus illness 2019 (COVID-19). CDC will replace this interim steerage as extra data turns into accessible.

Clinical Presentation

Incubation interval

The incubation interval for COVID-19 is believed to increase to 14 days, with a median time of 4-5 days from publicity to signs onset.1-3 One research reported that 97.5% of individuals with COVID-19 who develop signs will achieve this inside 11.5 days of SARS-CoV-2 an infection.3

Presentation

The indicators and signs of COVID-19 current at sickness onset range, however over the course of the illness, most individuals with COVID-19 will expertise the next1,4-9:

  • Fever or chills
  • Cough
  • Shortness of breath or problem respiratory
  • Fatigue
  • Muscle or physique aches
  • Headache
  • New lack of style or odor
  • Sore throat
  • Congestion or runny nostril
  • Nausea or vomiting
  • Diarrhea

Symptoms differ with severity of illness.  For instance, fever, cough, and shortness of breath are extra generally reported amongst people who find themselves hospitalized with COVID-19 than amongst these with milder illness (non-hospitalized sufferers). Atypical shows happen typically, and older adults and individuals with medical comorbidities might have delayed presentation of fever and respiratory signs.10,14 In one research of 1,099 hospitalized sufferers, fever was current in solely 44% at hospital admission however finally developed in 89% throughout hospitalization.1 Fatigue, headache, and muscle aches (myalgia) are among the many mostly reported signs in people who find themselves not hospitalized, and sore throat and nasal congestion or runny nostril (rhinorrhea) additionally could also be outstanding signs.  Many individuals with COVID-19  expertise gastrointestinal signs reminiscent of nausea, vomiting or diarrhea, typically previous to creating fever and decrease respiratory tract indicators and signs.9 Loss of odor (anosmia) or style (ageusia) previous the onset of respiratory signs has been generally reported in COVID-19 particularly amongst girls and younger or middle-aged sufferers who don’t require hospitalization.11,12 While most of the signs of COVID-19 are widespread to different respiratory or viral diseases, anosmia seems to be extra particular to COVID-19.12

Several research have reported that the indicators Signs and signs of COVID-19 in kids are just like adults range by age of the kid,  and are normally milder in comparison with adults.15-19 For extra data on the scientific presentation and course amongst kids, see Information for Pediatric Healthcare Providers.

Asymptomatic and Pre-Symptomatic Infection

Several research have documented SARS-CoV-2 an infection in sufferers who by no means develop signs (asymptomatic) and in sufferers not but symptomatic (pre-symptomatic).16,18,20-30 Since asymptomatic individuals aren’t routinely examined, the prevalence of asymptomatic an infection and detection of pre-symptomatic an infection will not be but nicely understood. One research discovered that as many as 13% of reverse transcription-polymerase chain response (RT-PCR)-confirmed circumstances of SARS-CoV-2 an infection in kids have been asymptomatic.16 Another research of expert nursing facility residents who have been contaminated with SARS-CoV-2 after contact with a healthcare employee with COVID-19 demonstrated that half of the residents have been asymptomatic or pre-symptomatic on the time of contact tracing, analysis, and testing.27 Patients might have abnormalities on chest imaging earlier than the onset of signs.21,22.

Asymptomatic and Pre-Symptomatic Transmission

Increasing numbers of epidemiologic research have documented SARS-CoV-2 transmission throughout the pre-symptomatic incubation interval,21,31-33. Virologic research utilizing RT-PCR detection have reported checks with  low cycle thresholds, indicating bigger portions of viral RNA and viable virus has been cultured from individuals with asymptomatic and pre-symptomatic SARS-CoV-2 an infection.25,27,30,34 The relationship between SARS-CoV-2 viral RNA shedding and  transmission threat will not be but clear. The proportion of SARS-CoV-2 transmission on account of asymptomatic or pre-symptomatic an infection in comparison with symptomatic an infection is unclear.35

Clinical Course

Illness Severity

The largest cohort reported of >44,000 individuals with COVID-19 from China confirmed that sickness severity can vary from delicate to important:36

  • Mild to reasonable (delicate signs as much as delicate pneumonia): 81%
  • Severe (dyspnea, hypoxia, or >50% lung involvement on imaging): 14%
  • Critical (respiratory failure, shock, or multiorgan system dysfunction): 5%

In this research, all deaths occurred amongst sufferers with important sickness, and the general case fatality charge was 2.3%.36 The case fatality charge amongst sufferers with important illness was 49%.36 Among kids in China, sickness severity was decrease with 94% having asymptomatic, delicate, or reasonable illness; 5% having extreme illness; and <1% having important illness.16 Among U.S. COVID-19 circumstances with identified disposition, the proportion of individuals who have been hospitalized was 19%.37 The proportion of individuals with COVID-19 admitted to the intensive care unit (ICU) was 6%.37

Clinical Progression

Among sufferers who developed extreme illness, the medium time to dyspnea from the onset of sickness or signs ranged from 5 to eight days, the median time to acute respiratory misery syndrome (ARDS) from the onset of sickness or signs ranged from Eight to 12 days, and the median time to ICU admission from the onset of sickness or signs ranged from 10 to 12 days.5,6,10,11 Clinicians ought to concentrate on the potential for some sufferers to quickly deteriorate one week after sickness onset. Among all hospitalized sufferers, a spread of 26% to 32% of sufferers have been admitted to the ICU.6,8,11 Among all sufferers, a spread of three% to 17% developed ARDS in comparison with a spread of 20% to 42% for hospitalized sufferers and 67% to 85% for sufferers admitted to the ICU.1,4-6,8,11 Mortality amongst sufferers admitted to the ICU ranges from 39% to 72% relying on the research and traits of affected person inhabitants.5,8,10,11 The median size of hospitalization amongst survivors was 10 to 13 days.1,6,8

Risk Factors for Severe Illness

Age is a powerful threat issue for extreme sickness, issues, and loss of life.1,6,8,14,36-40 Among >44,000 confirmed circumstances of COVID-19 in China, the case fatality charge was highest amongst older individuals: ≥80 years, 14.8%; 70–79 years, 8.0%; 60–69 years, 3.6%; 50–59 years, 1.3%; 40–49 years, 0.4%; <40 years, 0.2%.36,41 In early U.S. epidemiologic knowledge, case fatality was highest in individuals aged ≥85 years (vary 10%–27%), adopted by these aged 65-84 years (3%–11%), aged 55-64 years (1%–3%), and aged <55 years (<1%).37

Patients in China with no reported underlying medical circumstances had an general case fatality of 0.9%. Case fatality was increased for sufferers with comorbidities: 10.5% for these with heart problems, 7.3% for these with diabetes, and roughly 6% for these with power respiratory illness, or most cancers.1,6,14,36,38,41,42    Prior stroke, diabetes, power lung illness, and power kidney illness have all been related to elevated sickness severity and antagonistic outcomes. Serious heart conditions, together with coronary heart failure, coronary artery illness, congenital coronary heart illness, cardiomyopathies, and pulmonary hypertension, might put individuals at increased threat for extreme sickness from COVID-19. People with hypertension could also be at an elevated threat for extreme sickness from COVID-19 and will proceed to take their medicines as prescribed. At this time, individuals whose solely underlying medical situation is hypertension aren’t thought-about to be at increased threat for extreme sickness from COVID-19.43,44

Accounting for variations in age and prevalence of underlying situation, mortality related to COVID-19 reported within the United States has been just like experiences from China.26,37,39

Reinfection

There aren’t any knowledge regarding the opportunity of re-infection with SARS-CoV-2 after restoration from COVID-19. While viral RNA shedding declines with decision of signs, it might proceed for days to weeks.34,38,45 However, the detection of RNA throughout convalescence doesn’t essentially point out the presence of viable infectious virus. Clinical an infection has been correlated with the detection of IgM and IgG antibodies.46-49 However, definitive knowledge are missing, and it stays unsure whether or not people with antibodies are protected towards reinfection with SARS-CoV-2, and in that case, what focus of antibodies is required to confer safety.

Viral Testing

Diagnosis of COVID-19 requires detection of SARS-CoV-2 RNA by reverse transcription polymerase chain response (RT-PCR). Detection of SARS-CoV-2 viral RNA is healthier in nasopharynx samples in comparison with throat samples.34,50 Lower respiratory samples might have higher yield than higher respiratory samples.34,50 SARS-CoV-2 RNA has additionally been detected in stool and blood.15,45,47,51 Detection of SARS-CoV-2 RNA in blood could also be a marker of extreme sickness.52 Viral RNA shedding might persist over longer durations amongst older individuals and people who had extreme sickness requiring hospitalization (median vary of viral shedding amongst hospitalized sufferers 12–20 days).34,38,45,46,53

Infection with each SARS-CoV-2 and with different respiratory viruses has been reported, and detection of one other respiratory pathogen doesn’t rule out COVID-19.54

For extra details about testing and specimen assortment, dealing with and storage, go to Evaluating and Testing Persons for Coronavirus Disease 2019 (COVID-19) and Frequently Asked Questions on COVID-19 Testing at Laboratories.

Laboratory and Radiographic Findings

Laboratory Findings

Lymphopenia is the most typical laboratory discovering in COVID-19, and is present in as many as 83% of hospitalized sufferers.1,5 Lymphopenia, neutrophilia, elevated serum alanine aminotransferase and aspartate aminotransferase ranges, elevated lactate dehydrogenase, excessive CRP, and excessive ferritin ranges could also be related to better sickness severity.1,5,6,8,38,55 Elevated D-dimer and lymphopenia have been related to mortality.8,38 Procalcitonin is often regular on admission, however might improve amongst these admitted to an ICU.4-6 Patients with important sickness had excessive plasma ranges of inflammatory makers, suggesting potential immune dysregulation.5,56

Radiographic Findings

Chest radiographs of sufferers with COVID-19 usually display bilateral air-space consolidation, although sufferers might have unremarkable chest radiographs early within the illness.1,5,57 Chest CT photos from sufferers with COVID-19 usually display bilateral, peripheral floor glass opacities.4,8,36,58-67 Because this chest CT imaging sample is non-specific and overlaps with different infections, the diagnostic worth of chest CT imaging for COVID-19 could also be low and dependent upon radiographic interpretation.59,68 One research discovered that 56% of sufferers who offered inside two days of prognosis had a standard CT.60 Conversely, different research have recognized chest CT abnormalities in sufferers previous to the detection of SARS-CoV-2 RNA.58,69 Given the variability in chest imaging findings, chest radiograph or CT alone will not be advisable for the prognosis of COVID-19. The American College of Radiology additionally doesn’t advocate CT for screening, or as a first-line take a look at for prognosis of COVID-19. (See American College of Radiology Recommendationsexternal icon).

Clinical Management and Treatment

The National Institutes of Health printed pointers on prophylaxis use, testing, and administration of sufferers with COVID-19. For extra data, please go to National Institutes of Health: Coronavirus Disease 2019 (COVID-19) Treatment Guidelinesexternal icon. The suggestions have been primarily based on scientific proof and skilled opinion and will probably be up to date as extra knowledge turn into accessible.

Mild to Moderate Disease

Patients with a gentle scientific presentation (absence of viral pneumonia and hypoxia) might not initially require hospitalization, and plenty of sufferers will have the ability to handle their sickness at house. The choice to watch a affected person within the inpatient or outpatient setting needs to be made on a case-by-case foundation. This choice will depend upon the scientific presentation, requirement for supportive care, potential threat components for extreme illness, and the flexibility of the affected person to self-isolate at house. Patients with threat components for extreme sickness (see People Who Are at Higher Risk for Severe Illness) needs to be monitored carefully given the attainable threat of development to extreme sickness, particularly within the second week after symptom onset.5,6,14,38

For data concerning an infection prevention and management suggestions, please see Interim Infection Prevention and Control Recommendations for Patients with Confirmed Coronavirus Disease 2019 (COVID-19) or Persons Under Investigation for COVID-19 in Healthcare Settings.

Severe Disease

Some sufferers with COVID-19 may have extreme illness requiring hospitalization for administration. Inpatient administration revolves across the supportive administration of the most typical issues of extreme COVID-19: pneumonia, hypoxemic respiratory failure/ARDS, sepsis and septic shock, cardiomyopathy and arrhythmia, acute kidney harm, and issues from extended hospitalization, together with secondary bacterial infections, thromboembolism, gastrointestinal bleeding, and demanding sickness polyneuropathy/myopathy.1,4-6,14,36,38,70-73

More data could be discovered at National Institutes of Health: Coronavirus Disease 2019 (COVID-19) Treatment Guidelinesexternal icon and Healthcare Professionals: Frequently Asked Questions and Answers. Additional assets and steerage paperwork on the therapy and administration of COVID-19, together with inpatient administration of critically ailing sufferers, are supplied under.

Hypercoagulability and COVID-19

Some sufferers with COVID-19 might develop indicators of a hypercoagulable state and be at elevated threat for venous and arterial thrombosis of huge and small vessels.74,75  Laboratory abnormalities generally noticed amongst hospitalized sufferers with COVID-19-associated coagulopathy embrace:

  • Mild thrombocytopenia
  • Increased D-dimer ranges
  • Increased fibrin degradation merchandise
  • Prolonged prothrombin time

Elevated D-dimer ranges have been strongly related to better threat of loss of life.74,76-79

There are a number of experiences of hospitalized sufferers with thrombotic issues, most regularly deep venous thrombosis and pulmonary embolism.80-82 Other reported manifestations embrace:

  • Microvascular thrombosis of the toes
  • Clotting of catheters
  • Myocardial harm with ST-segment elevation
  • Large vessel strokes83-86

The pathogenesis for COVID-19-associated hypercoagulability stays unknown. However, hypoxia and systemic irritation secondary to COVID-19 might result in excessive ranges of inflammatory cytokines and activation of the coagulation pathway.

There are restricted knowledge accessible to tell scientific administration round prophylaxis or therapy of venous thromboembolism in COVID-19 sufferers.

Several nationwide skilled associations present assets for up-to-date data regarding COVID-19-associated hypercoagulability, together with administration of anticoagulation. This is a quickly evolving matter, with new data launched typically.

More data on hypercoagulability and COVID-19 is on the market from the American Society of Hematology external iconand National Institutes of Health: Coronavirus Disease 2019 (COVID-19) Treatment Guidelines – Antithrombotic Therapy in Patients with COVID-19external icon.

Pediatric Management

Illness amongst pediatric sufferers with COVID-19 is often milder than amongst adults. Most kids current with signs of higher respiratory an infection. However, extreme outcomes have been reported in kids, together with deaths. Data recommend that infants (<12 months of age) could also be at increased threat for extreme sickness from COVID-19 in contrast with older kids.16 CDC and companions are additionally investigating experiences of multisystem inflammatory syndrome in children (MIS-C) related to COVID-19.

For expanded steerage on the administration of kids with COVID-19 and related issues, see Evaluation and Management Considerations for Neonates At Risk for COVID-19Information for Pediatric Healthcare Providers, and the Surviving Sepsis Campaign International Guidelines for the Management of Septic Shock and Sepsis-Associated Organ Dysfunction in Childrenexternal icon.

Investigational Therapeutics

The National Institutes of Health have printed interim guidelines for the medical management of COVID-19external icon which embrace data on therapeutic choices for COVID-19 at the moment underneath investigation. No U.S. Food and Drug Administration (FDA)-approved medication have demonstrated security and efficacy in randomized managed trials when used to deal with sufferers with COVID-19, though FDA has granted an Emergency Use Authorization for the use of remdesivirexternal icon to deal with extreme circumstances. Use of investigational therapies for therapy of COVID-19 ought to ideally be performed within the context of enrollment in randomized managed trials, in order that useful medication could be recognized. For the most recent data, see Information for Clinicians on Therapeutic Options for COVID-19 Patients. For data on registered trials within the United States, see ClinicalTrials.govexternal icon.

Discontinuation of Transmission-Based Precautions or Home Isolation

Patients who’ve clinically recovered and are capable of discharge from the hospital, however who haven’t been cleared from their Transmission-Based Precautions, might proceed isolation at their place of residence till cleared. For suggestions on discontinuation of Transmission-Based Precautions or house isolation for sufferers who’ve recovered from COVID-19, please see:

  1. Guan WJ, Ni ZY, Hu Y, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med 2020;382:1708-20.
  2. Li Q, Guan X, Wu P, et al. Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia. N Engl J Med 2020;382:1199-207.
  3. Lauer SA, Grantz KH, Bi Q, et al. The Incubation Period of Coronavirus Disease 2019 (COVID-19) From Publicly Reported Confirmed Cases: Estimation and Application. Ann Intern Med 2020.
  4. Chen N, Zhou M, Dong X, et al. Epidemiological and scientific traits of 99 circumstances of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive research. Lancet 2020;395:507-13.
  5. Huang C, Wang Y, Li X, et al. Clinical options of sufferers contaminated with 2019 novel coronavirus in Wuhan, China. Lancet 2020;395:497-506.
  6. Wang D, Hu B, Hu C, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA 2020.
  7. Xu XW, Wu XX, Jiang XG, et al. Clinical findings in a gaggle of sufferers contaminated with the 2019 novel coronavirus (SARS-Cov-2) outdoors of Wuhan, China: retrospective case collection. BMJ 2020;368:m606.
  8. Wu C, Chen X, Cai Y, et al. Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China. JAMA Intern Med 2020.
  9. Pan L, Mu M, Yang P, et al. Clinical Characteristics of COVID-19 Patients With Digestive Symptoms in Hubei, China: A Descriptive, Cross-Sectional, Multicenter Study. Am J Gastroenterol 2020.
  10. Zhou F, Yu T, Du R, et al. Clinical course and threat components for mortality of grownup inpatients with COVID-19 in Wuhan, China: a retrospective cohort research. Lancet 2020.
  11. Yang X, Yu Y, Xu J, et al. Clinical course and outcomes of critically ailing sufferers with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational research. Lancet Respir Med 2020.
  12. Giacomelli A, Pezzati L, Conti F, et al. Self-reported olfactory and style issues in SARS-CoV-2 sufferers: a cross-sectional research. Clin Infect Dis 2020.
  13. Cai J, Xu J, Lin D, et al. A Case Series of kids with 2019 novel coronavirus an infection: scientific and epidemiological options. Clin Infect Dis 2020.
  14. Dong Y, Mo X, Hu Y, et al. Epidemiology of COVID-19 Among Children in China. Pediatrics 2020.
  15. Liu W, Zhang Q, Chen J, et al. Detection of Covid-19 in Children in Early January 2020 in Wuhan, China. N Engl J Med 2020;382:1370-1.
  16. Lu X, Zhang L, Du H, et al. SARS-CoV-2 Infection in Children. N Engl J Med 2020;382:1663-5.
  17. Wei M, Yuan J, Liu Y, Fu T, Yu X, Zhang ZJ. Novel Coronavirus Infection in Hospitalized Infants Under 1 Year of Age in China. JAMA 2020.
  18. Chan JF, Yuan S, Kok KH, et al. A familial cluster of pneumonia related to the 2019 novel coronavirus indicating person-to-person transmission: a research of a household cluster. Lancet 2020;395:514-23.
  19. Hu Z, Song C, Xu C, et al. Clinical traits of 24 asymptomatic infections with COVID-19 screened amongst shut contacts in Nanjing, China. Sci China Life Sci 2020;63:706-11.
  20. Wang Y, Liu Y, Liu L, Wang X, Luo N, Ling L. Clinical final result of 55 asymptomatic circumstances on the time of hospital admission contaminated with SARS-Coronavirus-2 in Shenzhen, China. J Infect Dis 2020.
  21. Pan X, Chen D, Xia Y, et al. Asymptomatic circumstances in a household cluster with SARS-CoV-2 an infection. Lancet Infect Dis 2020;20:410-1.
  22. Bai Y, Yao L, Wei T, et al. Presumed Asymptomatic Carrier Transmission of COVID-19. JAMA 2020.
  23. Kam KQ, Yung CF, Cui L, et al. A Well Infant with Coronavirus Disease 2019 (COVID-19) with High Viral Load. Clin Infect Dis 2020.
  24. McMichael TM, Clark S, Pogosjans S, et al. COVID-19 in a Long-Term Care Facility – King County, Washington, February 27-March 9, 2020. MMWR Morb Mortal Wkly Rep 2020;69:339-42.
  25. Kimball A, Hatfield KM, Arons M, et al. Asymptomatic and Presymptomatic SARS-CoV-2 Infections in Residents of a Long-Term Care Skilled Nursing Facility – King County, Washington, March 2020. MMWR Morb Mortal Wkly Rep 2020;69:377-81.
  26. Roxby AC, Greninger AL, Hatfield KM, et al. Detection of SARS-CoV-2 Among Residents and Staff Members of an Independent and Assisted Living Community for Older Adults – Seattle, Washington, 2020. MMWR Morb Mortal Wkly Rep 2020;69:416-8.
  27. Mizumoto Ok, Kagaya Ok, Zarebski A, Chowell G. Estimating the asymptomatic proportion of coronavirus illness 2019 (COVID-19) circumstances on board the Diamond Princess cruise ship, Yokohama, Japan, 2020. Euro Surveill 2020;25.
  28. Hoehl S, Rabenau H, Berger A, et al. Evidence of SARS-CoV-2 Infection in Returning Travelers from Wuhan, China. N Engl J Med 2020;382:1278-80.
  29. Wei WE, Li Z, Chiew CJ, Yong SE, Toh MP, Lee VJ. Presymptomatic Transmission of SARS-CoV-2 – Singapore, January 23-March 16, 2020. MMWR Morb Mortal Wkly Rep 2020;69:411-5.
  30. Tong ZD, Tang A, Li KF, et al. Potential Presymptomatic Transmission of SARS-CoV-2, Zhejiang Province, China, 2020. Emerg Infect Dis 2020;26:1052-4.
  31. Qian G, Yang N, Ma AHY, et al. A COVID-19 Transmission inside a household cluster by presymptomatic infectors in China. Clin Infect Dis 2020.
  32. Rothe C, Schunk M, Sothmann P, et al. Transmission of 2019-nCoV Infection from an Asymptomatic Contact in Germany. N Engl J Med 2020;382:970-1.
  33. Zou L, Ruan F, Huang M, et al. SARS-CoV-2 Viral Load in Upper Respiratory Specimens of Infected Patients. N Engl J Med 2020;382:1177-9.
  34. Young BE, Ong SWX, Kalimuddin S, et al. Epidemiologic Features and Clinical Course of Patients Infected With SARS-CoV-2 in Singapore. i 2020.
  35. Liu Y, Yan LM, Wan L, et al. Viral dynamics in delicate and extreme circumstances of COVID-19. Lancet Infect Dis 2020.
  36. To KK, Tsang OT, Leung WS, et al. Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses throughout an infection by SARS-CoV-2: an observational cohort research. Lancet Infect Dis 2020.
  37. Li R, Pei S, Chen B, et al. Substantial undocumented an infection facilitates the speedy dissemination of novel coronavirus (SARS-CoV-2). Science 2020;368:489-93.
  38. Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72314 Cases From the Chinese Center for Disease Control and Prevention. JAMA 2020.
  39. Team CC-R. Severe Outcomes Among Patients with Coronavirus Disease 2019 (COVID-19) – United States, February 12-March 16, 2020. MMWR Morb Mortal Wkly Rep 2020;69:343-6.
  40. Arentz M, Yim E, Klaff L, et al. Characteristics and Outcomes of 21 Critically Ill Patients With COVID-19 in Washington State. JAMA 2020.
  41. Livingston E, Bucher Ok. Coronavirus Disease 2019 (COVID-19) in Italy. JAMA 2020.
  42. Novel Coronavirus Pneumonia Emergency Response Epidemiology T. [The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) in China]. Zhonghua Liu Xing Bing Xue Za Zhi 2020;41:145-51.
  43. Team CC-R. Preliminary Estimates of the Prevalence of Selected Underlying Health Conditions Among Patients with Coronavirus Disease 2019 – United States, February 12-March 28, 2020. MMWR Morb Mortal Wkly Rep 2020;69:382-6.
  44. Zhang W, Du RH, Li B, et al. Molecular and serological investigation of 2019-nCoV contaminated sufferers: implication of a number of shedding routes. Emerg Microbes Infect 2020;9:386-9.
  45. Zhao J, Yuan Q, Wang H, et al. Antibody responses to SARS-CoV-2 in sufferers of novel coronavirus illness 2019. Clin Infect Dis 2020.
  46. Guo L, Ren L, Yang S, et al. Profiling Early Humoral Response to Diagnose Novel Coronavirus Disease (COVID-19). Clin Infect Dis 2020.
  47. Wang W, Xu Y, Gao R, et al. Detection of SARS-CoV-2 in Different Types of Clinical Specimens. JAMA 2020.
  48. Wu Y, Guo C, Tang L, et al. Prolonged presence of SARS-CoV-2 viral RNA in faecal samples. Lancet Gastroenterol Hepatol 2020;5:434-5.
  49. Chen W, Lan Y, Yuan X, et al. Detectable 2019-nCoV viral RNA in blood is a powerful indicator for the additional scientific severity. Emerg Microbes Infect 2020;9:469-73.
  50. Ding Q, Lu P, Fan Y, Xia Y, Liu M. The scientific traits of pneumonia sufferers coinfected with 2019 novel coronavirus and influenza virus in Wuhan, China. J Med Virol 2020.
  51. Zhang C, Shi L, Wang FS. Liver harm in COVID-19: administration and challenges. Lancet Gastroenterol Hepatol 2020;5:428-30.
  52. Qin C, Zhou L, Hu Z, et al. Dysregulation of immune response in sufferers with COVID-19 in Wuhan, China. Clin Infect Dis 2020.
  53. Shi H, Han X, Jiang N, et al. Radiological findings from 81 sufferers with COVID-19 pneumonia in Wuhan, China: a descriptive research. Lancet Infect Dis 2020.
  54. Shi H, Han X, Jiang N, et al. Radiological findings from 81 sufferers with COVID-19 pneumonia in Wuhan, China: a descriptive research. Lancet Infect Dis 2020;20:425-34.
  55. Ai T, Yang Z, Hou H, et al. Correlation of Chest CT and RT-PCR Testing in Coronavirus Disease 2019 (COVID-19) in China: A Report of 1014 Cases. Radiology 2020:200642.
  56. Bernheim A, Mei X, Huang M, et al. Chest CT Findings in Coronavirus Disease-19 (COVID-19): Relationship to Duration of Infection. Radiology 2020:200463.
  57. Lei J, Li J, Li X, Qi X. CT Imaging of the 2019 Novel Coronavirus (2019-nCoV) Pneumonia. Radiology 2020;295:18.
  58. Shi H, Han X, Zheng C. Evolution of CT Manifestations in a Patient Recovered from 2019 Novel Coronavirus (2019-nCoV) Pneumonia in Wuhan, China. Radiology 2020;295:20.
  59. Wang Y, Dong C, Hu Y, et al. Temporal Changes of CT Findings in 90 Patients with COVID-19 Pneumonia: A Longitudinal Study. Radiology 2020:200843.
  60. Xu X, Yu C, Qu J, et al. Imaging and scientific options of sufferers with 2019 novel coronavirus SARS-CoV-2. Eur J Nucl Med Mol Imaging 2020;47:1275-80.
  61. Yang W, Cao Q, Qin L, et al. Clinical traits and imaging manifestations of the 2019 novel coronavirus illness (COVID-19):A multi-center research in Wenzhou metropolis, Zhejiang, China. J Infect 2020;80:388-93.
  62. Zhao W, Zhong Z, Xie X, Yu Q, Liu J. Relation Between Chest CT Findings and Clinical Conditions of Coronavirus Disease (COVID-19) Pneumonia: A Multicenter Study. AJR Am J Roentgenol 2020;214:1072-7.
  63. Pan F, Ye T, Sun P, et al. Time Course of Lung Changes On Chest CT During Recovery From 2019 Novel Coronavirus (COVID-19) Pneumonia. Radiology 2020:200370.
  64. Bai HX, Hsieh B, Xiong Z, et al. Performance of radiologists in differentiating COVID-19 from viral pneumonia on chest CT. Radiology 2020:200823.
  65. Xie X, Zhong Z, Zhao W, Zheng C, Wang F, Liu J. Chest CT for Typical 2019-nCoV Pneumonia: Relationship to Negative RT-PCR Testing. Radiology 2020:200343.
  66. Guo T, Fan Y, Chen M, et al. Cardiovascular Implications of Fatal Outcomes of Patients With Coronavirus Disease 2019 (COVID-19). JAMA Cardiol 2020.
  67. Inciardi RM, Lupi L, Zaccone G, et al. Cardiac Involvement in a Patient With Coronavirus Disease 2019 (COVID-19). JAMA Cardiol 2020.
  68. Shi S, Qin M, Shen B, et al. Association of Cardiac Injury With Mortality in Hospitalized Patients With COVID-19 in Wuhan, China. JAMA Cardiol 2020.
  69. Tang N, Bai H, Chen X, Gong J, Li D, Sun Z. Anticoagulant therapy is related to decreased mortality in extreme coronavirus illness 2019 sufferers with coagulopathy. J Thromb Haemost 2020.
  70. Bikdeli, B; Madhavan, M; Jimenez,D et al. COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-up. Journal of American College of Cardiology. April 2020 , S0735-1097(20)35008-7 https://doi.org/10.1016/j.jacc.2020.04.031external icon
  71. Cannegieter, S; Klok, FA. COVID-19 related coagulopathy and thromboembolic illness: Commentary on an interim skilled steerage. Research and Practice in Thrombosis and Haemostasis, April 2020.  https://doi.org/10.1002/rth2.12350external icon
  72. Lippi G, Plebani M, Michael Henry B. Thrombocytopenia is related to extreme coronavirus illness 2019 (COVID-19) infections: A meta-analysis. Clinica Chimica Acta.2020 Mar 13;506:145-148. DOI:10.1016/j.cca.2020.03.022
  73. Lippi G, Favaloro EJ. D-dimer is related to severity of coronavirus illness 2019 (COVID-19): a pooled evaluation. Thrombosis and Haemostasis In press. DOI 10.1055/s-0040-1709650
  74. Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are related to poor prognosis in sufferers with novel coronavirus pneumonia. J Thromb Haemost Feb 2020. https://doi.org/10.1111/jth.14768
  75. American Venous Forum. Considerations in prophylaxis and therapy of VTE in COVID-19 Patients. 2020. Accessed April 2020 at https://www.veinforum.org/covid-19/external icon
  76. Klok, FA; Kruip, MJHA; van der Meer NJM et al. Incidence of thrombotic issues in critically ailing ICU sufferers with COVID-19. Thrombosis Research, April 2020. In Press https://doi.org/10.1016/j.thromres.2020.04.013external icon
  77. Helms, J; Tacquard, C; Severac, F et al.  High threat of thrombosis in sufferers in extreme SARS-CoV-2 an infection: a multicenter potential cohort research. Intensive Care Medicine, April 2020. In Press. DOI: 10.1007/s00134-020-06062-x
  78. Grillet, F; Behr, J; Calame, H et al.  Acute Pulmonary Embolism Associated with COVID-19 Pneumonia Detected by Pulmonary CT Angiography. Radiology. Published Online: Apr 23 2020 https://doi.org/10.1148/radiol.2020201544external icon
  79. Oxley, T; Mocco, J; Majidi,S et al. Large-Vessel Stroke as a Presenting Feature of Covid-19 within the Young. New England Journal of Medicine. April 2020. DOI: 10.1056/NEJMc2009787
  80. Li, Y; Wang, M; Zhou, Y et al.  Acute Cerebrovascular Disease Following COVID-19: A Single Center, Retrospective, Observational Study (3/3/2020). Available at SSRN: https://ssrn.com/abstract=3550025external icon
  81. Margo,C; Mulvey, J; Berlin, D et al. Complement related microvascular harm and thrombosis within the pathogenesis of extreme COVID-19 an infection: A report of 5 circumstances. Translational Research. April 2020 S1931-5244(20)30070-0. https://doi.org/10.1016/j.trsl.2020.04.007external icon
  82. Bangalore, S; Sharma, A; Slotwiner, A et al. ST-Segment Elevation in Patients with COVID-19-A Case Series. New England Journal of Medicine. April 17, 2020 DOI: 10.1056/NEJMc2009020
  83. National Institutes of Health. Covid-19 Treatment Guidelines. Accessed April 28, 2020 at: https://www.covid19treatmentguidelines.nih.gov/introduction/external icon

Leave a Comment

Item added to cart.
0 items - $0.00